The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback